vs
英格索兰（IR）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
英格索兰的季度营收约是瑞思迈的1.5倍（$2.1B vs $1.4B），瑞思迈净利率更高（27.6% vs 12.7%，领先14.9%），瑞思迈同比增速更快（11.0% vs 10.1%），过去两年英格索兰的营收复合增速更高（11.9% vs 7.8%）
英格索兰是一家美国跨国企业，主营流体生产及工业产品业务。公司于2020年2月由原英格索兰plc的工业业务板块分拆后与加德纳丹佛合并组建，旗下拥有40多个品牌，产品覆盖全球所有主要市场。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
IR vs RMD — 直观对比
营收规模更大
IR
是对方的1.5倍
$1.4B
营收增速更快
RMD
高出0.8%
10.1%
净利率更高
RMD
高出14.9%
12.7%
两年增速更快
IR
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.1B | $1.4B |
| 净利润 | $266.1M | $392.6M |
| 毛利率 | 42.6% | 61.8% |
| 营业利润率 | 18.7% | 34.6% |
| 净利率 | 12.7% | 27.6% |
| 营收同比 | 10.1% | 11.0% |
| 净利润同比 | 15.8% | 13.9% |
| 每股收益（稀释后） | $0.67 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IRRMD
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.1B | $1.4B | ||
| Q3 25 | $2.0B | $1.3B | ||
| Q2 25 | $1.9B | $1.3B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.9B | $1.3B | ||
| Q3 24 | $1.9B | $1.2B |
净利润IRRMD
| Q2 26 | — | $392.6M | ||
| Q1 26 | — | $398.7M | ||
| Q4 25 | $266.1M | $392.6M | ||
| Q3 25 | $244.1M | $348.5M | ||
| Q2 25 | $-115.3M | $379.7M | ||
| Q1 25 | $186.5M | $365.0M | ||
| Q4 24 | $229.8M | $344.6M | ||
| Q3 24 | $221.6M | $311.4M |
毛利率IRRMD
| Q2 26 | — | 61.8% | ||
| Q1 26 | — | 62.2% | ||
| Q4 25 | 42.6% | 61.8% | ||
| Q3 25 | 43.7% | 61.5% | ||
| Q2 25 | 43.7% | 60.8% | ||
| Q1 25 | 44.6% | 59.3% | ||
| Q4 24 | 42.9% | 58.6% | ||
| Q3 24 | 43.8% | 58.6% |
营业利润率IRRMD
| Q2 26 | — | 34.6% | ||
| Q1 26 | — | 34.9% | ||
| Q4 25 | 18.7% | 34.6% | ||
| Q3 25 | 19.2% | 33.4% | ||
| Q2 25 | 4.0% | 33.7% | ||
| Q1 25 | 17.6% | 33.0% | ||
| Q4 24 | 20.0% | 32.5% | ||
| Q3 24 | 19.1% | 31.6% |
净利率IRRMD
| Q2 26 | — | 27.6% | ||
| Q1 26 | — | 27.9% | ||
| Q4 25 | 12.7% | 27.6% | ||
| Q3 25 | 12.5% | 26.1% | ||
| Q2 25 | -6.1% | 28.2% | ||
| Q1 25 | 10.9% | 28.3% | ||
| Q4 24 | 12.1% | 26.9% | ||
| Q3 24 | 11.9% | 25.4% |
每股收益（稀释后）IRRMD
| Q2 26 | — | $2.68 | ||
| Q1 26 | — | $2.74 | ||
| Q4 25 | $0.67 | $2.68 | ||
| Q3 25 | $0.61 | $2.37 | ||
| Q2 25 | $-0.29 | $2.58 | ||
| Q1 25 | $0.46 | $2.48 | ||
| Q4 24 | $0.57 | $2.34 | ||
| Q3 24 | $0.54 | $2.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $1.4B |
| 总债务越低越好 | $4.8B | $663.8M |
| 股东权益账面价值 | $10.1B | $6.3B |
| 总资产 | $18.3B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.47× | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资IRRMD
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.6B | $932.7M | ||
| Q4 24 | $1.5B | $521.9M | ||
| Q3 24 | $1.4B | $426.4M |
总债务IRRMD
| Q2 26 | — | $663.8M | ||
| Q1 26 | — | $664.1M | ||
| Q4 25 | $4.8B | $403.9M | ||
| Q3 25 | $4.8B | $408.7M | ||
| Q2 25 | $4.8B | $658.4M | ||
| Q1 25 | $4.8B | $663.1M | ||
| Q4 24 | $4.8B | $662.9M | ||
| Q3 24 | $4.8B | $667.6M |
股东权益IRRMD
| Q2 26 | — | $6.3B | ||
| Q1 26 | — | $6.5B | ||
| Q4 25 | $10.1B | $6.3B | ||
| Q3 25 | $10.1B | $6.1B | ||
| Q2 25 | $10.1B | $6.0B | ||
| Q1 25 | $10.5B | $5.5B | ||
| Q4 24 | $10.2B | $5.3B | ||
| Q3 24 | $10.3B | $5.2B |
总资产IRRMD
| Q2 26 | — | $8.5B | ||
| Q1 26 | — | $8.8B | ||
| Q4 25 | $18.3B | $8.5B | ||
| Q3 25 | $18.2B | $8.3B | ||
| Q2 25 | $18.1B | $8.2B | ||
| Q1 25 | $18.4B | $7.6B | ||
| Q4 24 | $18.0B | $7.1B | ||
| Q3 24 | $18.2B | $7.2B |
负债/权益比IRRMD
| Q2 26 | — | 0.11× | ||
| Q1 26 | — | 0.10× | ||
| Q4 25 | 0.47× | 0.06× | ||
| Q3 25 | 0.47× | 0.07× | ||
| Q2 25 | 0.47× | 0.11× | ||
| Q1 25 | 0.45× | 0.12× | ||
| Q4 24 | 0.47× | 0.13× | ||
| Q3 24 | 0.47× | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $499.0M | — |
| 自由现金流经营现金流 - 资本支出 | $461.5M | — |
| 自由现金流率自由现金流/营收 | 22.1% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | 1.88× | — |
| 过去12个月自由现金流最近4个季度 | $1.2B | — |
8季度趋势，按日历期对齐
经营现金流IRRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $499.0M | $339.7M | ||
| Q3 25 | $354.6M | $457.3M | ||
| Q2 25 | $245.7M | $538.8M | ||
| Q1 25 | $256.4M | $578.7M | ||
| Q4 24 | $526.2M | $308.6M | ||
| Q3 24 | $404.0M | $325.5M |
自由现金流IRRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $461.5M | $311.2M | ||
| Q3 25 | $325.5M | $414.4M | ||
| Q2 25 | $210.4M | $508.2M | ||
| Q1 25 | $222.7M | $557.9M | ||
| Q4 24 | $490.9M | $288.0M | ||
| Q3 24 | $374.3M | $307.7M |
自由现金流率IRRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 21.9% | ||
| Q3 25 | 16.6% | 31.0% | ||
| Q2 25 | 11.1% | 37.7% | ||
| Q1 25 | 13.0% | 43.2% | ||
| Q4 24 | 25.9% | 22.5% | ||
| Q3 24 | 20.1% | 25.1% |
资本支出强度IRRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | 2.0% | ||
| Q3 25 | 1.5% | 3.2% | ||
| Q2 25 | 1.9% | 2.3% | ||
| Q1 25 | 2.0% | 1.6% | ||
| Q4 24 | 1.9% | 1.6% | ||
| Q3 24 | 1.6% | 1.5% |
现金转化率IRRMD
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.88× | 0.87× | ||
| Q3 25 | 1.45× | 1.31× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | 1.37× | 1.59× | ||
| Q4 24 | 2.29× | 0.90× | ||
| Q3 24 | 1.82× | 1.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IR
| Transferred At Point In Time | $1.5B | 71% |
| Transferred Over Time | $193.0M | 9% |
| Precision And Science Technologies Segment | $183.1M | 9% |
| Acquisitions In2024 | $175.6M | 8% |
| Acquisitions In2025 | $70.8M | 3% |
RMD
暂无分部数据
